An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies
暂无分享,去创建一个
Carlos Briones | Miguel Moreno | Víctor Parro | David Abia | E. Domingo | C. Perales | V. Martín | D. Abia | V. Parro | C. Briones | J. Alcamí | P. Garrido | Esteban Domingo | Celia Perales | J. García-Pérez | María Fernández-Algar | Verónica Martín | Helena G Dos Santos | Patricia Garrido | María Pernas | Javier García-Pérez | José Alcamí | José Luis Torán | M. Pernas | J. Torán | M. Moreno | H. G. Dos Santos | María Fernández-Algar | Patricia Garrido
[1] D. Kuritzkes,et al. Clinical implications of HIV-1 minority variants. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] E. Domingo,et al. Viral Quasispecies Evolution , 2012, Microbiology and Molecular Reviews.
[3] M. Kozal,et al. Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects , 2014, Viruses.
[4] E. Domingo,et al. Quasispecies as a matter of fact: Viruses and beyond , 2011, Virus Research.
[5] Kevin Dieckhaus,et al. Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use , 2009, PloS one.
[6] E. Domingo,et al. Minority memory genomes can influence the evolution of HIV-1 quasispecies in vivo. , 2006, Gene.
[7] Ronan Boulmé,et al. Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure , 2014, AIDS (London).
[8] Michael Monsour,et al. Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.
[9] Gregory S Turenchalk,et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.
[10] D. Persing,et al. Comparative Evaluation of Three Human Immunodeficiency Virus Genotyping Systems: the HIV-GenotypR Method, the HIV PRT GeneChip Assay, and the HIV-1 RT Line Probe Assay , 2000, Journal of Clinical Microbiology.
[11] E. Forgy. Cluster analysis of multivariate data : efficiency versus interpretability of classifications , 1965 .
[12] K. Metzner,et al. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. , 2013, The Journal of infectious diseases.
[13] N. Shen,et al. Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays , 1996, Nature Medicine.
[14] J. Drake,et al. Mutation rates among RNA viruses. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[15] Roger Paredes,et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. , 2010, The Journal of infectious diseases.
[16] F. E. Grubbs. Sample Criteria for Testing Outlying Observations , 1950 .
[17] D.M. Mount,et al. An Efficient k-Means Clustering Algorithm: Analysis and Implementation , 2002, IEEE Trans. Pattern Anal. Mach. Intell..
[18] K. Metzner,et al. Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data , 2012, Front. Microbio..
[19] K. Metzner,et al. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon . , 2015, The Journal of antimicrobial chemotherapy.
[20] B. Masquelier,et al. Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure , 2014, PloS one.
[21] W. Heneine,et al. Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy , 2015, PloS one.
[22] Raul Andino,et al. Quasispecies Theory and the Behavior of RNA Viruses , 2010, PLoS pathogens.
[23] K. Metzner,et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. , 2011, JAMA.
[24] A. Vallely,et al. Factors associated with antiretroviral treatment uptake and adherence: a review. Perspectives from Australia, Canada, and the United Kingdom , 2015, AIDS care.
[25] Matthias Cavassini,et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] B. Larder,et al. Performance of the Affymetrix GeneChip HIV PRT 440 Platform for Antiretroviral Drug Resistance Genotyping of Human Immunodeficiency Virus Type 1 Clades and Viral Isolates with Length Polymorphisms , 1999, Journal of Clinical Microbiology.
[27] K. Metzner,et al. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. , 2013, The Journal of infectious diseases.
[28] S. Franco,et al. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine. , 2007, Journal of molecular biology.
[29] M. Eigen. On the nature of virus quasispecies. , 1996, Trends in microbiology.
[30] C. Briones,et al. Structural analysis of hepatitis C RNA genome using DNA microarrays. , 2004, Nucleic acids research.
[31] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[32] C. Delaugerre,et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996–2006 in France , 2009, AIDS.
[33] M. Poljak,et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. , 2009, The Journal of infectious diseases.
[34] C. Briones,et al. The folding of the hepatitis C virus internal ribosome entry site depends on the 3′-end of the viral genome , 2012, Nucleic acids research.
[35] E. Domingo,et al. Microarray-based identification of antigenic variants of foot-and-mouth disease virus: a bioinformatics quality assessment , 2006, BMC Genomics.
[36] M. Kozal,et al. New technology to detect low-level drug-resistant HIV variants , 2011 .
[37] E. Domingo,et al. Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications. , 2008, AIDS reviews.
[38] Richard Gibson,et al. Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use? , 2014, Current Infectious Disease Reports.
[39] K. Metzner,et al. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[40] M. Poljak,et al. Primary resistance to integrase strand-transfer inhibitors in Europe. , 2015, The Journal of antimicrobial chemotherapy.
[41] Robert W. Shafer,et al. HIV-1 Antiretroviral Resistance , 2012, Drugs.
[42] Rodolphe Thiébaut,et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy , 2008, AIDS.
[43] R. Paredes,et al. Minority HIV-1 drug-resistant mutations and prevention of mother-to-child transmission: perspectives for resource-limited countries. , 2014, AIDS reviews.
[44] Niko Beerenwinkel,et al. Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies , 2010, Nucleic acids research.
[45] S. Hammer,et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. , 2010, The Journal of infectious diseases.
[46] E. Domingo,et al. Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. , 2000, Virus research.
[47] M. Tanner,et al. Development of a simple microarray for genotyping HIV‐1 drug resistance mutations in the reverse transcriptase gene in rural Tanzania , 2014, Tropical medicine & international health : TM & IH.
[48] Cristina Romero-López,et al. End-to-end crosstalk within the hepatitis C virus genome mediates the conformational switch of the 3′X-tail region , 2013, Nucleic acids research.
[49] E. Domingo,et al. Duration and fitness dependence of quasispecies memory. , 2002, Journal of molecular biology.
[50] Claudia Stewart,et al. Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA , 2013, Retrovirology.
[51] C. Vidal,et al. Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations , 2014, PloS one.
[52] B. Berkhout,et al. HIV-1 drug-resistance and drug-dependence , 2007, Retrovirology.
[53] Jan Albert,et al. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[54] M. Poljak,et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe , 2014, BMC Infectious Diseases.
[55] Miguel Ángel Martínez,et al. Role of a dipeptide insertion between codons 69 and 70 of HIV‐1 reverse transcriptase in the mechanism of AZT resistance , 2000, The EMBO journal.
[56] E. Domingo,et al. Memory in Viral Quasispecies , 2000, Journal of Virology.
[57] J. Kop,et al. Sensitivity and Specificity of the ViroSeq Human Immunodeficiency Virus Type 1 (HIV-1) Genotyping System for Detection of HIV-1 Drug Resistance Mutations by Use of an ABI PRISM 3100 Genetic Analyzer , 2005, Journal of Clinical Microbiology.
[58] R. Sanjuán,et al. Variability in the mutation rates of RNA viruses , 2014 .
[59] Jerome H. Kim,et al. Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis , 2015, PLoS Medicine.
[60] M. Poljak,et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. , 2011, AIDS reviews.
[61] K. Borroto-Esoda,et al. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy , 2011, AIDS.
[62] Eduardo Eyras,et al. Structural basis for the biological relevance of the invariant apical stem in IRES-mediated translation , 2011, Nucleic acids research.
[63] V. Johnson,et al. Accuracy of the TRUGENE HIV-1 Genotyping Kit , 2003, Journal of Clinical Microbiology.
[64] M. Wainberg,et al. Human Immunodeficiency Virus Proviral DNA from Peripheral Blood and Lymph Nodes Demonstrates Concordant Resistance Mutations to Zidovudine (Codon 215) and Didanosine (Codon 74) , 1998 .
[65] E. Domingo,et al. The impact of quasispecies dynamics on the use of therapeutics. , 2012, Trends in microbiology.
[66] E. Martínez-Salas,et al. Structural analysis provides insights into the modular organization of picornavirus IRES. , 2011, Virology.
[67] J. Hoheisel,et al. Genotypic resistance testing in HIV by arrayed primer extension , 2008, Analytical and bioanalytical chemistry.
[68] L. Menéndez-Arias,et al. Mechanistic insights into the role of Val75 of HIV-1 reverse transcriptase in misinsertion and mispair extension fidelity of DNA synthesis. , 2008, Journal of molecular biology.
[69] M. Capobianchi,et al. Next-generation sequencing technology in clinical virology. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[70] Carmen Molina-París,et al. Memory in Retroviral Quasispecies: Experimental Evidence and Theoretical Model for Human Immunodeficiency Virus , 2003, Journal of Molecular Biology.
[71] Chen Liang,et al. Multidrug-resistant variants of HIV type 1 (HIV-1) can exist in cells as defective quasispecies and be rescued by superinfection with other defective HIV-1 variants. , 2009, The Journal of infectious diseases.